BRNS - Company ID 0001828185
The table below shows Barinthus Biotherapeutics plc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $14.97M | $802.00K | $44.70M | $268.00K | $4.82M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $25.56M | $42.24M | $44.87M | $42.35M | $20.37M | $14.39M |
| SG&A |
Barinthus Biotherapeutics plc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $14.97M in fiscal 2024. Over the 6 fiscal years shown, annual revenue declined from $4.82M (FY 2020) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $40.83M |
| $29.67M |
| $39.84M |
| $6.39M |
| $25.12M |
| $10.48M |
| Operating income | -$70.56M | -$67.97M | -$83.91M | -$4.04M | -$45.22M | -$20.05M |
| Income tax | -$175.00K | -$44.00K | -$3.08M | -$4.47M | -$28.00K | $95.00K |
| Net income | -$66.43M | -$61.07M | -$73.35M | $5.34M | -$50.87M | -$17.71M |
| EPS (diluted) | -$1.64 | -$1.55 | -$1.91 | $0.14 | -$1.96 | -$2.24 |